Last reviewed · How we verify
remifentanil-based
Remifentanil-based, marketed by Konkuk University Medical Center, holds a position in the anesthetic market with its key composition patent expiring in 2028. The drug's primary strength lies in its rapid onset and short duration of action, making it highly suitable for procedural sedation and anesthesia. The primary risk is the potential increase in generic competition following the 2028 patent expiry.
At a glance
| Generic name | remifentanil-based |
|---|---|
| Sponsor | Konkuk University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Hemodynamic Effects of Remimazolam vs Propofol During Robot-assisted Gynecologic Surgery (NA)
- Comparison of Target-Controlled and Manual Total Intravenous Anesthesia in Supratentorial Surgery (NA)
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Effect of Titrated Administration of Ciprofol on Perioperative Hypotension in Elderly Patients Undergoing Laparoscopic Abdominal Surgery: A Randomized Controlled Trial (NA)
- Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Tranexamic Acid Dose and Remifentanil Titration in Septorhinoplasty
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- remifentanil-based CI brief — competitive landscape report
- remifentanil-based updates RSS · CI watch RSS
- Konkuk University Medical Center portfolio CI